All In Biotech

Free tool

FAERS Monitor: Lybalvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213378 or its brand name (Lybalvi, Olanzapine, Samidorphan L-Malate). Reports on generic versions are filed under their own applications.

Reports

1,687

Serious

418

25% of reports

Hospitalization

187

Death reported

18

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use306
  • contraindicated product administered139
  • weight increased91
  • dizziness89
  • drug withdrawal syndrome77
  • insomnia76
  • nausea70
  • weight decreased68
  • vomiting64
  • feeling abnormal61
  • somnolence59
  • fatigue56
  • sedation56
  • decreased appetite53
  • anxiety50

Reports by year received

View as table
YearReports
20151
20191
202151
2022360
2023355
2024322
2025338
2026259

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,472 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contraindicated product administeredSignal13957.549.07,636
sedationSignal5626.720.61,359
drug withdrawal syndromeSignal7710.98.8688
weight increasedSignal915.14.1296
off label useSignal3064.43.9822
somnolenceSignal593.72.8112
insomniaSignal763.62.9139
feeling abnormalSignal613.22.590
weight decreasedSignal683.02.492
decreased appetiteSignal532.82.262
dizzinessSignal892.21.860
anxietySignal502.21.732
vomiting641.71.318
nausea701.10.91
fatigue560.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.